New Study Highlights Potential of SS-68 in Treating Heart Rhythm Disorders

Understanding Heart Rhythm Disorders

A recent pre-clinical study has identified a new aminoindole derivative, SS-68, as a promising treatment for heart rhythm disorders by normalizing the heart’s electrical activity. Heart rhythm disorders, commonly referred to as cardiac arrhythmias, disrupt the regular heart rate, which for adults typically ranges from 60 to 100 beats per minute. These disorders can manifest as a heart rate that is too fast, too slow, or irregular, primarily caused by interruptions or disturbances in the heart’s electrical signal pathways.

Prevalence and Risks of Heart Rhythm Disorders

According to the Cardiac Arrhythmia Network of Canada, millions of Canadians are currently affected by irregular heart rhythms, leading to approximately 40,000 deaths annually. As the population ages, this figure is projected to rise. Various heart diseases contribute to the development of rhythm disorders, including coronary artery disease, previous heart attacks, high blood pressure, and valve disease.

While some individuals may not exhibit any symptoms, others might experience irregular heartbeats, shortness of breath, chest pain, dizziness, or paleness. These conditions significantly increase the risk of stroke and heart attack, adversely impacting the quality of life.

Current Treatment Options

Numerous medications are available to manage arrhythmias by controlling heart rate and rhythm or preventing blood clots. However, many current antifibrillatory drugs have a limited therapeutic window, meaning that the difference between effective and toxic doses is narrow.

Research on SS-68 and Its Cardio-Pharmacological Activity

A study published in the Journal of Research Results in Pharmacology details the efforts of Russian researchers who have developed a reliable model to evaluate aminoindole derivatives, focusing on SS-68 as a potential alternative compound with enhanced cardio-pharmacological activity.

The research team tested this compound under various conditions and across different animal models, concluding that SS-68 successfully normalizes heart electrical activity. Notably, it demonstrated a superior anti-arrhythmic effect compared to existing medications such as amiodarone, lidocaine, aymaline, ethacizine, etmozine, and quinidine anaprilin.

Additionally, in cases of brain injury-induced heart rhythm disorders, SS-68 proved effective in reducing spike waves, sharp waves, and spike-and-wave activities. The compound also showed significant promise in treating blocked blood vessels by enhancing coronary blood flow.

Future Research Directions

SS-68 presents as a promising pharmacological agent for treating heart rhythm disorders. However, further comprehensive research is essential to assess potential side effects and adverse events before establishing its safety and efficacy.

Author Information

Written by Man-tik Choy, Ph.D.

Reference

Bogus, S.K. 2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1 H-indole hydrochloride (SS-68): Antiarrhythmic and cardioprotective activity and its molecular mechanisms of action (Part I). Research Results in Pharmacology, 4(2):133-150. DOI: 10.3897/rrpharmacology.4.28592